Dilemmas in drug development for tropical diseases: Experience with praziquantel

Health Policy

Volumn 44, Issue 1, 1998, Pages 1-18

  Reich, Michael R ^a   Govindaraj, Ramesh ^b  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b WORLD BANK   (United States)

Author keywords

Drug development; Pharmaceutical policy; Praziquantel; Public private cooperation; Schistosomiasis

Indexed keywords

PRAZIQUANTEL;

ARTICLE; DRUG BIOAVAILABILITY; DRUG COST; DRUG FORMULATION; DRUG MARKETING; EGYPT; GOVERNMENT; HEALTH CARE POLICY; HUMAN; HUMAN TISSUE; KOREA; SCHISTOSOMIASIS; TEAMWORK; TROPICAL DISEASE;

ANTHELMINTICS; DEVELOPING COUNTRIES; DRUG COSTS; DRUG INDUSTRY; HEALTH POLICY; HEALTH SERVICES ACCESSIBILITY; HUMANS; INTERNATIONAL COOPERATION; POVERTY; PRAZIQUANTEL; PRIVATE SECTOR; PUBLIC SECTOR; SCHISTOSOMIASIS; TROPICAL MEDICINE;

EID: 0031840168     PISSN: 01688510     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8510(98)00002-5     Document Type: Article

References (29)

1. Grady C. The Search for an AIDS Vaccine: Ethical Issues in the Development and Testing of a New HIV Vaccine. 1995;Indiana University Press, Bloomington.
2. Reich M.R., Govindaraj R., Dumbaugh K., Yang B.M., Brinkmann A., El-Saharty S. International Strategies for Tropical Disease Treatment: Experiences with Praziquantel. DAP-CTD Research Report. 1998;World Health Organization, Geneva.
3. Hunter J.M., Rey L., Adekolu-John E.O., Mott K.E. Parasitic Diseases in Water Resources Development. 1993;World Health Organization, Geneva.
4. Groll E. Praziquantel. Advanced Pharmacology Chemotherapy, 1984;20:219-38.
5. Andrews P. et al. Praziquantel. Medicinal Research Review. 3(2):1983;147-200.
6. Wegner DHG. The profile of the trematodicidal compound praziquantel. Arzneimittel-Forschung/Drug Research, 1984; 34(II) (96):1132-6.
7. Seubert J., Pohlke R., Loebick F. Synthesis and properties of praziquantel, a novel broad spectrum anthelmintic with excellent activity against schistosomes and cestodes. Experentia. 33:1997;1036-1037.
8. King C.H., Mahmoud A.A. Drugs five years later: praziquantel. Annals of Internal Medicine. 110(4):1989;290-296.
9. World Health Organization. The Control of Schistosomiasis. Report of a WHO Expert Committee, Technical Report Series no. 728, Geneva: World Health Organization, 1985.
10. Liu L.X., Weller P.F. Antiparasitic drugs. New England Journal of Medicine. 334:1996;1178-1184.
11. Menas Associates. Pharmaceutical industry struggles with price controls. Egypt Focus, 1992.
12. Barakat R., El Masry A.G., Farghaly A. et al. Impact of population-based selective chemotherapy on prevalence and intensity of schistosoma mansoni infections in the Nile Delta: Kafr El Sheikh. Tropical and Geographical Medicine. 47:1995;266-270.
13. El Malatawy A., El Habashy A., Lechine N. et al. Selective population chemotherapy among schoolchildren in Beheira Governorate: the UNICEF/Arab Republic of Egypt/WHO schistosomiasis control project. Bulletin of the World Health Organization. 70:1992;47-56.
14. Farag M.K., El-Shazly A.M., Khashaba M.T. et al. Impact of the current national bilharzia control programme on the epidemiology of schistosomiasis mansoni in an Egyptian village. Transactions of the Royal Society of Tropical Medicine and Hygiene. 87:1993;250-253.
15. Utroska JA, Chen MG, Dixon H, et al. An Estimate of the Global Needs for Praziquantel within Schistosomiasis Control Programmes. Geneva: World Health Organization, 1989.
16. Board on International Health, Institute of Medicine. America's Vital Interest in Global Health, Washington, DC: National Academy Press, 1997.
17. Rapp R., Rozek R. Benefits and costs of intellectual property protection in developing countries. Journal of World Trade. 24:1990;75-102.
18. Weiss S, Merck & Co, Inc. Case no. 90-013, Stanford, CA: The Business Enterprise Trust, 1991.
19. Tavis L.A. Power and Responsibility: Multinational Managers and Developing Country Concerns. 1997;244-275 University of Notre Dame Press, Notre Dame, IN.
20. Horn H., Shy O. Bundling and international market segmentation. International Economic Review. 37(1):1996;51-69.
21. Kremer M. A mechanism for encouraging innovation. HIID Discussion paper no. 533. Cambridge: Harvard Institute for International Development, May 1996.
22. Williams N. Tropical diseases: drug companies decline to collaborate. Science 1997;278:1704.
23. Reich M.R. The political economy of health transitions in the third world. Chen L.C., Kleinman A., Ware N.C. Health and Social Change in International Perspective. 1994;413-451 Harvard School of Public Health, Boston.
24. World Bank, World Development Report 1993: Investing in Health. New York: Oxford University Press, 1993.
25. Kinnon CM. WTO: What's in it for WHO? WHO Task Force on Health Economics. Geneva: World Health Organization, 1995.
26. Joshi M.M. TRIPS: a review needed. The Eastern Pharmacist (India). 40(471):1997;39-44.
27. Love JP. A consumer perspective on proposals as they relate to rules regarding intellectual property. Presented to the 3rd Trade Ministerial and Americas Business Forum, Belo Horizonte, Brazil, May 13-16, 1997.
28. Alford WP. To Steal a Book is an Elegant Offense: Intellectual Property Law in Chinese Civilization, Stanford, CA: Stanford University Press, 1995.
29. Anon. Piracy on the high Cs. The Economist, February 17 (1996) 17-18.